
Marjory Moreau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11657604/publications.pdf Version: 2024-02-01



#	Article	IF	CITATION
1	Considerations for Improving Metabolism Predictions for In Vitro to In Vivo Extrapolation. Frontiers in Toxicology, 2022, 4, 894569.	3.1	10
2	Kinetics of metabolism of deltamethrin and cis- and trans-permethrin inÂvitro. Studies using rat and human liver microsomes, isolated rat hepatocytes and rat liver cytosol. Xenobiotica, 2021, 51, 40-50.	1.1	0
3	Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans. Toxicological Sciences, 2020, 173, 86-99.	3.1	29
4	Quantitative bias analysis of the association between subclinical thyroid disease and two perfluoroalkyl substances in a single study. Environmental Research, 2020, 182, 109017.	7.5	9
5	Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling. Computational Toxicology, 2020, 13, 100115.	3.3	15
6	The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay. Toxicology and Applied Pharmacology, 2020, 387, 114774.	2.8	10
7	Metabolism of bifenthrin, β-cyfluthrin, λ-cyhalothrin, cyphenothrin and esfenvalerate by rat and human cytochrome P450 and carboxylesterase enzymes. Xenobiotica, 2020, 50, 1434-1442.	1.1	6
8	Differential lymphatic versus portal vein uptake of the synthetic pyrethroids deltamethrin and cis-permethrin in rats. Toxicology, 2020, 443, 152563.	4.2	2
9	Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids. Toxicological Sciences, 2020, 176, 460-469.	3.1	5
10	Metabolism of deltamethrin and <i>cis</i> - and <i>trans</i> -permethrin by human expressed cytochrome P450 and carboxylesterase enzymes. Xenobiotica, 2019, 49, 521-527.	1.1	17
11	Evaluation of Age-Related Pyrethroid Pharmacokinetic Differences in Rats: Physiologically-Based Pharmacokinetic Model Development Using In Vitro Data and In Vitro to In Vivo Extrapolation. Toxicological Sciences, 2019, 169, 365-379.	3.1	19
12	Using exposure prediction tools to link exposure and dosimetry for risk-based decisions: A case study with phthalates. Chemosphere, 2017, 184, 1194-1201.	8.2	22
13	Comparison of the kinetics of various biomarkers of benzo[<i>a</i>]pyrene exposure following different routes of entry in rats. Journal of Applied Toxicology, 2015, 35, 781-790.	2.8	11
14	Kinetics of Diol and Hydroxybenzo[a]pyrene Metabolites in Relation to DNA Adduct Formation and Gene Expression in Rats. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2015, 78, 725-746.	2.3	5
15	Effects of Intravenous Benzo[a]Pyrene Dose Administration on Levels of Exposure Biomarkers, DNA Adducts, and Gene Expression in Rats. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2015, 78, 166-184.	2.3	10